Entry Point Capital, LLC Travere Therapeutics, Inc. Transaction History
Entry Point Capital, LLC
- $112 Billion
- Q1 2024
A detailed history of Entry Point Capital, LLC transactions in Travere Therapeutics, Inc. stock. As of the latest transaction made, Entry Point Capital, LLC holds 4,101 shares of TVTX stock, worth $39,615. This represents 0.03% of its overall portfolio holdings.
Number of Shares
4,101Holding current value
$39,615% of portfolio
0.03%Shares
1 transactions
Others Institutions Holding TVTX
# of Institutions
184Shares Held
91.5MCall Options Held
66.9KPut Options Held
265K-
Black Rock Inc. New York, NY7.8MShares$75.3 Million0.0% of portfolio
-
Armistice Capital, LLC New York, NY7.5MShares$72.5 Million0.79% of portfolio
-
Deep Track Capital, LP Greenwich, CT7.37MShares$71.2 Million1.88% of portfolio
-
State Street Corp Boston, MA6.61MShares$63.8 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA6.27MShares$60.5 Million0.0% of portfolio
About Travere Therapeutics, Inc.
- Ticker TVTX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 64,173,600
- Market Cap $620M
- Description
- Travere Therapeutics, Inc., a biopharmaceutical company, focuses on the identification, development, commercialization, and delivering of therapies for the treatment of rare diseases. Its marketed products include Chenodal, a synthetic oral form of chenodeoxycholic acid for the treatment of radiolucent stones in gallbladders; Cholbam, a cholic a...